triiodothyronine has been researched along with Depressive Disorder, Major in 44 studies
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In an open trial, we investigated the efficacy of triiodothyronine (T(3)) adjuvant to selective serotonin reuptake inhibitors (SSRIs) in subjects with major depressive disorder (MDD) resistant to SSRI treatment." | 9.11 | An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. ( Alpert, JE; Fava, M; Iosifescu, DV; Mischoulon, D; Nierenberg, AA; Papakostas, GI; Perlis, RH; Ryan, JL, 2005) |
| " This study aimed to establish the effects of fluoxetine and sertraline treatments on thyroid function and thyroid autoimmunity in patients with major depression and primary hypothyroidism and in patients with major depression and normal thyroid function." | 5.14 | Effects of selective serotonin reuptake inhibitors on thyroid function in depressed patients with primary hypothyroidism or normal thyroid function. ( Bahls, SC; Boeving, A; de Carvalho, GA; Graf, H, 2009) |
| "In an open trial, we investigated the efficacy of triiodothyronine (T(3)) adjuvant to selective serotonin reuptake inhibitors (SSRIs) in subjects with major depressive disorder (MDD) resistant to SSRI treatment." | 5.11 | An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. ( Alpert, JE; Fava, M; Iosifescu, DV; Mischoulon, D; Nierenberg, AA; Papakostas, GI; Perlis, RH; Ryan, JL, 2005) |
| "Previously we found that late pregnancy total and free thyroxine (TT4, FT4) concentrations were negatively related to greater pre and/or postpartum depressive symptoms." | 3.83 | Late pregnancy thyroid-binding globulin predicts perinatal depression. ( Garcia, N; Johnson, J; Leserman, J; Meltzer-Brody, S; Pedersen, C; Stansbury, M, 2016) |
| "One hundred thirteen patients with major depressive disorder were randomly assigned to 8 wk of double-blind outpatient treatment with low-dose T3 (25 microg), high-dose T3 (25 microg twice daily), or placebo in addition to paroxetine 30 mg daily." | 2.71 | Triiodothyronine addition to paroxetine in the treatment of major depressive disorder. ( Appelhof, BC; Brouwer, JP; Fliers, E; Hoogendijk, WJ; Huyser, J; Schene, AH; Tijssen, JG; van Dyck, R; Wiersinga, WM, 2004) |
| " After 4 weeks of treatment with sertraline at a standard dosage of 50 mg/day, both the single TRH test and the combined T3/TRH test were repeated in the depressed patients." | 2.71 | The influence of 4-week treatment with sertraline on the combined T3/TRH test in depressed patients. ( Alajbegovic, L; Baghai, TC; Eser, D; Möller, HJ; Rupprecht, R; Schaaf, L; Schüle, C; Schwarz, M; Zwanzger, P, 2005) |
| "Major depressive disorder is a severe, disabling disorder that affects around 4." | 2.61 | Monoaminergic system and depression. ( Berrocoso, E; González-Saiz, F; Mico, JA; Perez-Caballero, L; Romero-López-Alberca, C; Torres-Sanchez, S, 2019) |
| "Hypothyroidism has been linked to depression as there is irrefutable evidence that it triggers affective disease and psychic disorders." | 2.49 | Hypothyroidism and depression: salient aspects of pathogenesis and management. ( Duntas, LH; Maillis, A, 2013) |
| " T3 was well tolerated in most of the studies and adverse effects do not seem to be an impediment to clinical use." | 2.44 | Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. ( Cooper-Kazaz, R; Lerer, B, 2008) |
| "Thyroid dysfunction is common in major depressive disorder (MDD) patients; however, its relationship with psychotic depression (PD) remains unclear." | 1.91 | Association between thyroid hormones and comorbid psychotic symptoms in patients with first-episode and drug-naïve major depressive disorder. ( Chen, S; Hao, Y; Li, H; Li, M; Liu, T; Liu, Y; Ma, Y; Peng, P; Ren, H; Wang, Q; Wang, X; Wang, Y; Wu, Q; Yang, Q; Zhang, X; Zhou, Y, 2023) |
| "Treatment with clomipramine alone allowed five patients to achieve sustained remission (MADRS < or = 8), while three patients were responders (MADRS decrease > or = 50%) and three patients were partial responders (MADRS decrease > 25%)." | 1.35 | Is there a place for tricyclic antidepressants and subsequent augmentation strategies in obtaining remission for patients with treatment resistant depression? ( Aubry, JM; Bertschy, G; Bondolfi, G; Gervasoni, N; Gex-Fabry, M, 2009) |
| " This case series shows that T(3) may be successfully employed as a long term treatment augmentation of major depression if over time dosage levels are increased beyond the traditional 50 mcg." | 1.35 | Long term augmentation with T3 in refractory major depression. ( Kelly, TF; Lieberman, DZ, 2009) |
| "Phosphocreatine, which has a buffer role for ATP, decreased in treatment responders compared with nonresponders." | 1.35 | Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. ( Bolo, NR; Fava, M; Iosifescu, DV; Jensen, JE; Nierenberg, AA; Renshaw, PF, 2008) |
| "Major depressive disorder has been associated with changes in the hypothalamus-pituitary-thyroid (HPT) axis and with hypercortisolism." | 1.33 | Thyroid and adrenal axis in major depression: a controlled study in outpatients. ( Appelhof, BC; Brouwer, JP; Endert, E; Fliers, E; Hoogendijk, WJ; Huyser, J; Schene, AH; Tijssen, JG; Van Dyck, R; Wiersinga, WM; Zuketto, C, 2005) |
| "However, the information in regard to low T3 syndrome in psychiatric subjects who are clinically euthyroid and do not have any other systemic illness is scanty." | 1.33 | Low T3 syndrome in psychiatric depression. ( Kabir, MA; Premachandra, BN; Williams, IK, 2006) |
| "One hundred and one patients with major depressive disorder receiving their first antidepressant for their current major depressant episode had baseline thyroid function test performed." | 1.30 | Peripheral thyroid hormone levels in treatment resistant depression. ( Joffe, RT, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.55) | 18.7374 |
| 1990's | 1 (2.27) | 18.2507 |
| 2000's | 25 (56.82) | 29.6817 |
| 2010's | 14 (31.82) | 24.3611 |
| 2020's | 2 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Peng, P | 1 |
| Wang, Q | 1 |
| Ren, H | 1 |
| Zhou, Y | 1 |
| Hao, Y | 1 |
| Chen, S | 1 |
| Wu, Q | 1 |
| Li, M | 1 |
| Wang, Y | 2 |
| Yang, Q | 1 |
| Wang, X | 1 |
| Liu, Y | 1 |
| Ma, Y | 1 |
| Li, H | 1 |
| Liu, T | 1 |
| Zhang, X | 1 |
| Tost, M | 1 |
| Monreal, JA | 1 |
| Armario, A | 1 |
| Barbero, JD | 1 |
| Cobo, J | 1 |
| García-Rizo, C | 1 |
| Bioque, M | 1 |
| Usall, J | 1 |
| Huerta-Ramos, E | 1 |
| Soria, V | 1 |
| Labad, J | 1 |
| Perez-Caballero, L | 1 |
| Torres-Sanchez, S | 1 |
| Romero-López-Alberca, C | 1 |
| González-Saiz, F | 1 |
| Mico, JA | 1 |
| Berrocoso, E | 1 |
| Feng, G | 1 |
| Kang, C | 1 |
| Yuan, J | 1 |
| Zhang, Y | 1 |
| Wei, Y | 1 |
| Xu, L | 1 |
| Zhou, F | 1 |
| Fan, X | 1 |
| Yang, J | 1 |
| Homan, P | 1 |
| Drevets, WC | 1 |
| Hasler, G | 1 |
| Duntas, LH | 1 |
| Maillis, A | 1 |
| Wei, J | 2 |
| Sun, G | 2 |
| Zhao, L | 2 |
| Liu, X | 1 |
| Lin, D | 1 |
| Li, T | 1 |
| Ma, X | 2 |
| Baek, JH | 1 |
| Kang, ES | 1 |
| Fava, M | 4 |
| Mischoulon, D | 2 |
| Nierenberg, AA | 3 |
| Lee, D | 1 |
| Heo, JY | 1 |
| Jeon, HJ | 1 |
| Mohagheghi, A | 1 |
| Arfaie, A | 1 |
| Amiri, S | 1 |
| Nouri, M | 1 |
| Abdi, S | 1 |
| Safikhanlou, S | 1 |
| Yang, X | 1 |
| Huang, B | 1 |
| Zhou, B | 1 |
| Tao, L | 1 |
| Pedersen, C | 1 |
| Leserman, J | 1 |
| Garcia, N | 1 |
| Stansbury, M | 1 |
| Meltzer-Brody, S | 1 |
| Johnson, J | 1 |
| Stipcević, T | 1 |
| Pivac, N | 1 |
| Kozarić-Kovacić, D | 1 |
| Mück-Seler, D | 1 |
| Karlsson, H | 1 |
| Gervasoni, N | 1 |
| Aubry, JM | 1 |
| Gex-Fabry, M | 1 |
| Bertschy, G | 1 |
| Bondolfi, G | 1 |
| Papakostas, GI | 2 |
| Cooper-Kazaz, R | 4 |
| Appelhof, BC | 3 |
| Posternak, MA | 1 |
| Johnson, DP | 1 |
| Klibanski, A | 1 |
| Lerer, B | 5 |
| Kelly, TF | 1 |
| Lieberman, DZ | 1 |
| de Carvalho, GA | 1 |
| Bahls, SC | 1 |
| Boeving, A | 1 |
| Graf, H | 1 |
| Plaza, A | 1 |
| Garcia-Esteve, L | 1 |
| Ascaso, C | 1 |
| Navarro, P | 1 |
| Gelabert, E | 1 |
| Halperin, I | 1 |
| Valdés, M | 1 |
| Martín-Santos, R | 1 |
| Chilakamarri, G | 1 |
| Weismantel, D | 1 |
| Weismantel, A | 1 |
| Cohen, A | 1 |
| Dunlop, BW | 2 |
| DeFife, JA | 1 |
| Marx, L | 1 |
| Garlow, SJ | 2 |
| Nemeroff, CB | 2 |
| Lilienfeld, SO | 1 |
| Rosenthal, LJ | 1 |
| Goldner, WS | 1 |
| O'Reardon, JP | 1 |
| Ninan, PT | 1 |
| Agid, O | 1 |
| Corruble, E | 1 |
| Berlin, I | 1 |
| Lemoine, A | 1 |
| Hardy, P | 1 |
| Brouwer, JP | 2 |
| van Dyck, R | 2 |
| Fliers, E | 2 |
| Hoogendijk, WJ | 2 |
| Huyser, J | 2 |
| Schene, AH | 2 |
| Tijssen, JG | 2 |
| Wiersinga, WM | 2 |
| Endert, E | 1 |
| Zuketto, C | 1 |
| Schüle, C | 1 |
| Baghai, TC | 1 |
| Alajbegovic, L | 1 |
| Schwarz, M | 1 |
| Zwanzger, P | 1 |
| Eser, D | 1 |
| Schaaf, L | 1 |
| Möller, HJ | 1 |
| Rupprecht, R | 1 |
| Monteleone, P | 1 |
| Fabrazzo, M | 1 |
| Martiadis, V | 1 |
| Serritella, C | 1 |
| Pannuto, M | 1 |
| Maj, M | 1 |
| Iosifescu, DV | 2 |
| Perlis, RH | 1 |
| Ryan, JL | 1 |
| Alpert, JE | 1 |
| Abraham, G | 1 |
| Milev, R | 1 |
| Stuart Lawson, J | 1 |
| Premachandra, BN | 1 |
| Kabir, MA | 1 |
| Williams, IK | 1 |
| Fountoulakis, KN | 1 |
| Kantartzis, S | 1 |
| Siamouli, M | 1 |
| Panagiotidis, P | 1 |
| Kaprinis, S | 1 |
| Iacovides, A | 1 |
| Kaprinis, G | 1 |
| Valenstein, M | 1 |
| Joffe, RT | 2 |
| Sokolov, ST | 1 |
| Levitt, AJ | 1 |
| Posternak, M | 1 |
| Novak, S | 1 |
| Stern, R | 1 |
| Hennessey, J | 1 |
| Joffe, R | 1 |
| Prange, A | 1 |
| Zimmerman, M | 1 |
| Apter, JT | 1 |
| Cohen, R | 1 |
| Karagichev, L | 1 |
| Muhammed-Moussa, S | 1 |
| Grupper, D | 1 |
| Drori, T | 1 |
| Newman, ME | 1 |
| Sackeim, HA | 1 |
| Glaser, B | 1 |
| Bolo, NR | 1 |
| Jensen, JE | 1 |
| Renshaw, PF | 1 |
| Berlim, MT | 1 |
| Fleck, MP | 1 |
| Turecki, G | 1 |
| Nelson, JC | 1 |
| Eggers, C | 1 |
| Takahashi, S | 1 |
| Kondo, H | 1 |
| Yoshimura, M | 1 |
| Ochi, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder: A Randomized Controlled Trial[NCT04975100] | Phase 4 | 60 participants (Actual) | Interventional | 2021-08-26 | Completed | ||
| Thyroid Axis in Major Depression[NCT00208702] | Phase 4 | 153 participants (Actual) | Interventional | 1996-09-30 | Completed | ||
| Biochemical Brain Changes Correlated With The Antidepressant Effect Of Thyroid Hormones[NCT00562367] | 30 participants (Actual) | Interventional | 2001-10-31 | Completed | |||
| Triiodothyronine (T3) Supplementation in Bipolar and Unipolar Depression: A Random Assignment, Double Blind, Placebo-Controlled Study.[NCT00158990] | Phase 3 | 220 participants | Interventional | 2002-10-31 | Completed | ||
| Evaluation of Transcranial Photobiomodulation in Autism Spectrum Disorder: Double-Blind, Placebo-Controlled, Randomized Clinical Study of a Novel Approach[NCT05363982] | 54 participants (Anticipated) | Interventional | 2022-02-11 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for triiodothyronine and Depressive Disorder, Major
| Article | Year |
|---|---|
Targeting Hormones for Improving Cognition in Major Mood Disorders and Schizophrenia: Thyroid Hormones and Prolactin.
Topics: Bipolar Disorder; Cognition Disorders; Depressive Disorder, Major; Humans; Hypothyroidism; Mood Diso | 2020 |
Monoaminergic system and depression.
Topics: Antidepressive Agents; Antipsychotic Agents; Biogenic Monoamines; Buspirone; Depressive Disorder, Ma | 2019 |
Hypothyroidism and depression: salient aspects of pathogenesis and management.
Topics: Age Factors; Antidepressive Agents; Autoantibodies; Biomarkers; Depressive Disorder, Major; Drug Res | 2013 |
Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies.
Topics: Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Humans; Randomized Contr | 2009 |
Peripheral thyroid dysfunction in depression.
Topics: Antidepressive Agents; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Hypothalamo-Hy | 2006 |
Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors.
Topics: Adult; Aged; Depressive Disorder, Major; Drug Evaluation; Drug Synergism; Female; Humans; Male; Meta | 2008 |
Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview.
Topics: Antidepressive Agents; Antipsychotic Agents; Comorbidity; Depressive Disorder, Major; Drug Resistanc | 2008 |
Augmentation strategies in the treatment of major depressive disorder. Recent findings and current status of augmentation strategies.
Topics: Antidepressive Agents; Delayed-Action Preparations; Depressive Disorder, Major; Drug Synergism; Drug | 2007 |
[Psychotropic drug therapy in children].
Topics: Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; | 1977 |
15 trials available for triiodothyronine and Depressive Disorder, Major
| Article | Year |
|---|---|
Neural correlates of free T3 alteration after catecholamine depletion in subjects with remitted major depressive disorder and in controls.
Topics: Adolescent; Adult; alpha-Methyltyrosine; Case-Control Studies; Catecholamines; Cross-Over Studies; D | 2014 |
Preventive effect of liothyronine on electroconvulsive therapy-induced memory deficit in patients with major depressive disorder: a double-blind controlled clinical trial.
Topics: Adult; Depressive Disorder, Major; Double-Blind Method; Electroconvulsive Therapy; Female; Humans; M | 2015 |
Effects of selective serotonin reuptake inhibitors on thyroid function in depressed patients with primary hypothyroidism or normal thyroid function.
Topics: Adult; Aged; Autoantibodies; Depressive Disorder, Major; Fluoxetine; Humans; Hypothyroidism; Iodide | 2009 |
The effects of sertraline on psychopathic traits.
Topics: Adult; Antidepressive Agents; Antisocial Personality Disorder; Comorbidity; Depressive Disorder, Maj | 2011 |
The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder.
Topics: Adolescent; Adult; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Femal | 2012 |
Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation.
Topics: Adult; Aged; Algorithms; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Synergis | 2003 |
Should major depression with 'high normal' thyroid-stimulating hormone be treated preferentially with tricyclics?
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Tricycl | 2004 |
Triiodothyronine addition to paroxetine in the treatment of major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Dose-Response Relations | 2004 |
The influence of 4-week treatment with sertraline on the combined T3/TRH test in depressed patients.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents; Depressive Disorder, Major; Electrochemist | 2005 |
An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder.
Topics: Adult; Depressive Disorder; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; | 2005 |
T3 augmentation of SSRI resistant depression.
Topics: Adult; Aged; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Dis | 2006 |
Keeping our eyes on STAR*D.
Topics: Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Therapy, Combination; H | 2006 |
Lithium and triiodothyronine augmentation of antidepressants.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Administration S | 2006 |
A pilot effectiveness study: placebo-controlled trial of adjunctive L-triiodothyronine (T3) used to accelerate and potentiate the antidepressant response.
Topics: Adult; Algorithms; Antidepressive Agents; Combined Modality Therapy; Depressive Disorder, Major; Dou | 2008 |
Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; M | 2007 |
20 other studies available for triiodothyronine and Depressive Disorder, Major
| Article | Year |
|---|---|
Association between thyroid hormones and comorbid psychotic symptoms in patients with first-episode and drug-naïve major depressive disorder.
Topics: Depressive Disorder, Major; Humans; Psychotic Disorders; Thyroid Hormones; Thyrotropin; Thyroxine; T | 2023 |
Neuroendocrine abnormalities associated with untreated first episode patients with major depressive disorder and bipolar disorder.
Topics: Adrenocorticotropic Hormone; Adult; Bipolar Disorder; Depressive Disorder, Major; Endocrine System; | 2019 |
Hair thyroid hormones concentration in patients with depression changes with disease episodes in female Chinese.
Topics: Adolescent; Adult; China; Depressive Disorder, Major; Female; Hair; Humans; Middle Aged; Severity of | 2014 |
Thyroid stimulating hormone and serum, plasma, and platelet brain-derived neurotrophic factor during a 3-month follow-up in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Biomarkers; Blood Platelets; Brain-Derived Neurotrophic Factor; Depres | 2014 |
Comparison of hair thyroid hormones between first-episode and recurrent patients with depression in female Chinese.
Topics: Adolescent; Adult; China; Depressive Disorder, Major; Female; Hair; Humans; Middle Aged; Recurrence; | 2016 |
Late pregnancy thyroid-binding globulin predicts perinatal depression.
Topics: Adult; Anxiety; Depression, Postpartum; Depressive Disorder, Major; Female; Humans; Predictive Value | 2016 |
Thyroid activity in patients with major depression.
Topics: Adult; Biomarkers; Depressive Disorder, Major; Female; Humans; Hypothalamo-Hypophyseal System; Male; | 2008 |
Remission in depression--is it a realistic goal?
Topics: Antidepressive Agents; Chronic Disease; Citalopram; Cognitive Behavioral Therapy; Combined Modality | 2008 |
Is there a place for tricyclic antidepressants and subsequent augmentation strategies in obtaining remission for patients with treatment resistant depression?
Topics: Adult; Antidepressive Agents, Tricyclic; Clomipramine; Depressive Disorder, Major; Drug Resistance; | 2009 |
Long term augmentation with T3 in refractory major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Res | 2009 |
Childhood sexual abuse and hypothalamus-pituitary-thyroid axis in postpartum major depression.
Topics: Adult; Autoantibodies; Autoantigens; Child; Child Abuse, Sexual; Depression, Postpartum; Depressive | 2010 |
Can nonantidepressants help treat depression?
Topics: Antidepressive Agents; Antipsychotic Agents; Cohort Studies; Depressive Disorder, Major; Drug Therap | 2009 |
Noradrenergic adverse effects due to combined treatment with reboxetine and triiodothyronine.
Topics: Adult; Depressive Disorder, Major; Drug Synergism; Drug Therapy, Combination; Humans; Male; Middle A | 2010 |
T3 augmentation in major depressive disorder: safety considerations.
Topics: Adult; Depressive Disorder, Major; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Tr | 2011 |
Thyroid and adrenal axis in major depression: a controlled study in outpatients.
Topics: Adrenal Glands; Adult; Contraception; Depressive Disorder, Major; Estrogen Replacement Therapy; Estr | 2005 |
Circulating brain-derived neurotrophic factor is decreased in women with anorexia and bulimia nervosa but not in women with binge-eating disorder: relationships to co-morbid depression, psychopathology and hormonal variables.
Topics: Adult; Anorexia Nervosa; Body Mass Index; Brain-Derived Neurotrophic Factor; Bulimia; Comorbidity; D | 2005 |
Low T3 syndrome in psychiatric depression.
Topics: Depressive Disorder, Major; Euthyroid Sick Syndromes; Humans; Triiodothyronine | 2006 |
Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder.
Topics: Adenosine Triphosphate; Adult; Antidepressive Agents; Brain; Depressive Disorder, Major; Drug Therap | 2008 |
Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder.
Topics: Adenosine Triphosphate; Adult; Antidepressive Agents; Brain; Depressive Disorder, Major; Drug Therap | 2008 |
Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder.
Topics: Adenosine Triphosphate; Adult; Antidepressive Agents; Brain; Depressive Disorder, Major; Drug Therap | 2008 |
Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder.
Topics: Adenosine Triphosphate; Adult; Antidepressive Agents; Brain; Depressive Disorder, Major; Drug Therap | 2008 |
Peripheral thyroid hormone levels in treatment resistant depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Drug Resistance; Female; Humans; Male; Sev | 1999 |
Thyrotropin responses to TRH in depressive illness: relation to clinical subtypes and prolonged duration of depressive episode.
Topics: Adjustment Disorders; Adolescent; Adult; Aged; Bipolar Disorder; Depression; Depressive Disorder, Ma | 1974 |